$BTSG · BrightSpring Health Services, Inc.
BrightSpring Health Services reported Q3 2026 results with revenue of $4.213B (+26.4% YoY), GAAP diluted EPS from continuing operations of $0.46, and Adjusted EBITDA of $228M (+42.0% YoY). The company raised full-year 2026 guidance to revenue of $15.9B–$16.125B and Adjusted EBITDA of $850M–$860M, reflecting 37.6%–39.3% growth.
- Q3 revenue of $4.213B, up 26.4% YoY from $3.334B
- Adjusted EBITDA of $228M, up 42.0% YoY from $160M
- Net income from continuing operations of $101M vs $38M in Q3 2025
- Leverage improved to 1.79x from 2.15x at June 30, 2026
- Full-year 2026 revenue guidance raised to $15.9B–$16.125B, Adjusted EBITDA to $850M–$860M
Extended-hours trading shows BTSG at $64.28, +6.73% vs the regular-session close of $60.22, indicating strong positive reaction to the beat-and-raise quarter.
A 42% Adjusted EBITDA jump, raised guidance, and leverage dropping to 1.79x signal accelerating operating momentum at scale for the $11.9B home-health platform.
BrightSpring's 26% revenue growth and 42% Adjusted EBITDA expansion significantly outpace typical home-health and pharmacy peers, driven by the Amedisys/LHC branch acquisition and organic script revenue-per-script gains of 24%.
Reliance on Medicare/Medicaid reimbursement rates and PBM contracts; changes in drug pricing or pharmaceutical supplier relationships could pressure Pharmacy segment margins.